Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 10/10/2006, Updated: 01/15/2008) - In this trial, patients with completely resected pancreatic cancer will receive adjuvant chemotherapy and radiation therapy plus additional treatment with either bevacizumab or cetuximab, monoclonal antibodies that target different proteins important for cancer growth and spread.
Stress Management Therapy for Chemotherapy Patients
(Posted: 01/08/2008) - In this study, patients with newly diagnosed cancer and scheduled to undergo chemotherapy will be randomly assigned to one of two groups. One group will receive standard psychosocial care along with stress management training, while the other will receive standard psychosocial care alone.
Bevacizumab for Hormone-Refractory Prostate Cancer
(Posted: 09/05/2006, Updated: 12/26/2007) - In this trial, men with hormone-refractory prostate cancer that has spread (metastasized) will receive standard chemotherapy with the drugs docetaxel and prednisone. Half of the participants will be randomly assigned to additionally receive treatment with a monoclonal antibody called bevacizumab.
Extending Immunotherapy for Metastatic Melanoma
(Posted: 08/08/2006, Updated: 12/26/2007) - This study will assess the safety and antitumor activity of lymphocytes that have been genetically engineered to recognize the MART-1 antigen in patients with metastatic melanoma.
Treating Hereditary Thyroid Cancer in Children
(Posted: 12/18/2007) - In this clinical trial, doctors are testing a new drug called vandetanib (Zactima) in young patients with advanced hereditary medullary thyroid cancer. Vandetanib targets the specific genetic defect responsible for these tumors.